MLANA and Miyoshi myopathy: As shown by Venn diagrams, the 4g signature defined as 4g-H50 + 4g-M50 comprising all MM except those with expression of MGRN1, PMEL, MLANA, and TYRP1 simultaneously below the median (4g-L50), identified 84% of TNM-F patients with OS shorter than 5 years, with a 34% false discovery rate (FDR) (4g-H50 + 4g-M50 patients with long OS) (Figure 7d).